Curis Closes $80.8 Million PIPE Financing to Advance Emavusertib Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: PRnewswire
- Successful Financing: Curis, Inc. has successfully closed a PIPE financing round, securing up to $80.8 million in gross proceeds, including approximately $20.2 million in initial proceeds, which will provide crucial funding for the development of its drug emavusertib, supporting the company's ongoing growth in the biotechnology sector.
- Investor Participation: The financing attracted participation from several healthcare-focused institutional investors, including Nantahala Capital and Stonepine Capital Management, reflecting strong market confidence in Curis and its development pipeline, thereby enhancing the company's capital foundation.
- Drug Development Progress: Emavusertib, a small molecule IRAK4 and FLT3 inhibitor, is currently undergoing clinical trials for relapsed/refractory primary central nervous system lymphoma and has received Orphan Drug Designation from the FDA, indicating its potential market value in the treatment landscape.
- Future Development Plans: Curis plans to continue advancing emavusertib in both monotherapy and combination treatments for acute myeloid leukemia, and with this financing, the company expects to accelerate its clinical development process, enhancing its competitiveness in the biopharmaceutical industry.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like CRIS with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on CRIS
Wall Street analysts forecast CRIS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRIS is 11.00 USD with a low forecast of 5.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.916
Low
5.00
Averages
11.00
High
17.00
Current: 0.916
Low
5.00
Averages
11.00
High
17.00
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Curis Closes $80.8 Million PIPE Financing to Advance Emavusertib Development
- Successful Financing: Curis, Inc. has successfully closed a PIPE financing round, securing up to $80.8 million in gross proceeds, including approximately $20.2 million in initial proceeds, which will provide crucial funding for the development of its drug emavusertib, supporting the company's ongoing growth in the biotechnology sector.
- Investor Participation: The financing attracted participation from several healthcare-focused institutional investors, including Nantahala Capital and Stonepine Capital Management, reflecting strong market confidence in Curis and its development pipeline, thereby enhancing the company's capital foundation.
- Drug Development Progress: Emavusertib, a small molecule IRAK4 and FLT3 inhibitor, is currently undergoing clinical trials for relapsed/refractory primary central nervous system lymphoma and has received Orphan Drug Designation from the FDA, indicating its potential market value in the treatment landscape.
- Future Development Plans: Curis plans to continue advancing emavusertib in both monotherapy and combination treatments for acute myeloid leukemia, and with this financing, the company expects to accelerate its clinical development process, enhancing its competitiveness in the biopharmaceutical industry.
Continue Reading
Curis Closes $80.8 Million PIPE Financing to Advance Cancer Drug Development
- Successful Financing: Curis, Inc. has closed a PIPE financing of up to $80.8 million, with initial gross proceeds of approximately $20.2 million, significantly enhancing the company's financial capacity to advance the development of its cancer drug emavusertib.
- Investor Participation: The financing attracted participation from several healthcare-focused institutional investors, including Nantahala Capital and Stonepine Capital Management, reflecting strong market confidence in Curis's future growth prospects.
- Drug Development Progress: Emavusertib is currently undergoing clinical trials for relapsed/refractory primary central nervous system lymphoma, which is expected to provide new treatment options for patients and further solidify the company's position in the biotechnology sector.
- Strategic Collaboration: Curis's collaboration with Aurigene Discovery Technologies grants it exclusive rights to develop emavusertib, with plans to continue clinical research in areas such as acute myeloid leukemia, thereby expanding its therapeutic portfolio.
Continue Reading